Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus  by Diaz, Fernando M. & Knipe, David M.
Virology 488 (2016) 61–67Contents lists available at ScienceDirectVirologyhttp://d
0042-68
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroProtection from genital herpes disease, seroconversion
and latent infection in a non-lethal murine genital infection model
by immunization with an HSV-2 replication-defective mutant virus
Fernando M. Diaz, David M. Knipe n
Department of Microbiology and Immunobiology, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, United Statesa r t i c l e i n f o
Article history:
Received 3 August 2015
Returned to author for revisions
29 October 2015
Accepted 30 October 2015








22/& 2015 Elsevier Inc. All rights reserved.
esponding author.
ail address: david_knipe@hms.harvard.edu (Da b s t r a c t
Viral vaccines have traditionally protected against disease, but for viruses that establish latent infection,
it is desirable for the vaccine to reduce infection to reduce latent infection and reactivation. While ser-
oconversion has been used in clinical trials of herpes simplex virus (HSV) vaccines to measure protection
from infection, this has not been modeled in animal infection systems. To measure the ability of a genital
herpes vaccine candidate to protect against various aspects of infection, we established a non-lethal
murine model of genital HSV-2 infection, an ELISA assay to measure antibodies speciﬁc for infected cell
protein 8 (ICP8), and a very sensitive qPCR assay. Using these assays, we observed that immunization
with HSV-2 dl5-29 virus reduced disease, viral shedding, seroconversion, and latent infection by the
HSV-2 challenge virus. Therefore, it may be feasible to obtain protection against genital disease, ser-
oconversion and latent infection by immunization, even if sterilizing immunity is not achieved.
& 2015 Elsevier Inc. All rights reserved.Introduction
Viral vaccines have traditionally protected against viral disease
but have not necessarily protected completely against viral infec-
tion, because these pathogens cause acute infection and are
cleared by the host immune response (Graham et al., 2013).
Viruses such as the herpesviruses and HIV, which establish a latent
infection, provide a greater challenge because immunization
should ideally reduce infection as much as possible to prevent
establishment of latent infection, from which the virus could
reactivate and cause disease. However, the chickenpox vaccine is a
very successful vaccine as measured by reduction of disease and
results in a remarkable decrease in varicella incidence, even
though it does not completely prevent acute infection and latent
infection by wild-type virus (Gershon, 2013). The goal of HIV
vaccines has been to reduce viral load as much as possible. It is
widely recognized that there is an immediate need for a genital
herpes vaccine because this pathogen presents a great burden on
public health. Furthermore, there is a clear co-epidemic of HSV
and HIV, and herpes infection signiﬁcantly increases HIV acquisi-
tion and transmission (Barnabas and Celum, 2012). Therefore,
reducing or suppressing herpetic disease and/or infection is a.M. Knipe).desirable goal as it would decrease viral spread and improve herd
immunity.
Therapeutic trials of genital herpes vaccine candidates have
measured clinical disease such as the rate and number of recur-
rences, the duration and severity of the ﬁrst recurrence (Straus et
al., 1997). A limited number of clinical trials have tested the efﬁ-
cacy of various HSV-2 vaccine candidates as prophylactic vaccines
in humans. First, the Chiron subunit vaccine containing recombi-
nant HSV-2 glycoproteins B and D was administered with MF59 as
an adjuvant in a prophylactic vaccine study (Corey et al., 1999). In
this study, the endpoints were seroconversion, viral shedding and
manifestation of herpetic lesions. Even though vaccinated subjects
developed neutralizing antibodies, this vaccine failed to prevent
infection or disease, showing that neutralizing antibodies are not
sufﬁcient to control the virus.
In a subsequent study, the GSK HSV-2 glycoprotein D vaccine
candidate with alum-MPL as adjuvant was used as the immunogen
(Stanberry et al., 2002). The primary endpoint was protection from
herpetic disease. Although this vaccine produced humoral and
cellular responses, subjects were not protected from herpetic
disease. Of note, minor protection was observed but only in
women that were HSV-1 and -2 seronegative. In light of these
results, a second trial was conducted to evaluate the efﬁcacy of
subunit vaccines. This study was conducted on HSV-1 and 2 sero-
negative women (Belshe et al., 2012) testing the gD-2 alum for-
mulation. Again, the primary endpoint was protection from genital
Fig. 1. Disease and viral shedding in mice infected intravaginally with HSV-2
186ΔKpn. Mice were infected intravaginally with varying doses of HSV-2 186ΔKpn
virus, and disease and viral shedding were monitored. Five animals per group were
evaluated. (A) Disease scores in BALB/c mice infected intravaginally with HSV-2
186ΔKpn, (B) Viral shedding in the vaginal cavity of mice infected intravaginally
with HSV-2 186ΔKpn.
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disease or HSV-2 disease. Unfortunately, this trial showed no
efﬁcacy of this vaccine candidate against genital herpes disease
and no efﬁcacy against HSV-2 disease. Various arguments have
been made for prophylactic versus therapeutic vaccines for HSV-2
(Dropulic and Cohen, 2012; Johnston et al., 2011). An effective
therapeutic vaccine is likely to be more difﬁcult to attain than a
prophylactic vaccine, but a therapeutic vaccine trial requires fewer
trial subjects, can be conducted more rapidly, and is less expensive
(Dropulic and Cohen, 2012). Nevertheless, both prophylactic and
therapeutic vaccines for HSV are desirable.
Herpes vaccine studies in animals have aimed at measuring
protection from disease or lethality. None of the existing animal
infection systems is a perfect model for HSV infection. The mouse
models often have lethality as an endpoint, allowing only mea-
surements of protection from acute disease (Johnston et al., 2011).
The guinea pig model also requires a high dose of challenge virus
to elicit disease, and those that do not succumb to the infection
show reactivation for a limited period of time (Stanberry et al.,
1982). In this model, only protection from herpetic disease, both
acute and recurrent, has been measured, and no protection from
seroconversion has been shown, although some studies have
indicated protection from acute disease as a prophylactic effect
(Veselenak et al., 2012).
Recently, the needs for more standardized endpoints and ani-
mal models and for more clinically relevant endpoints in the
animal studies have been expressed by investigators in the ﬁeld
(Knipe et al., 2014). Here, we present a non-lethal mouse model of
genital herpes that allows the comparison of immunized and
unimmunized animals after challenge because even unimmunized
animals do not succumb to disease. Interestingly, our results
indicate that immunization with the dl5-29 vaccine candidate may
provide prophylactic protection against infection in this mouse
model, as measured by seroconversion.Results
Establishment of a non-lethal mouse model for genital HSV-2
infection
Genital challenge with wild-type (WT) HSV-2 in mice commonly
results in the death of the animals. When we reduced the genital
challenge dose of WT HSV-2 virus below that of the LD50, we
observed that some animals progressed through all stages of her-
petic disease including rear leg paralysis, but the animals that did
not succumb to the disease did not show any sign of acute or latent
infection at these low doses (results not shown). To establish a non-
lethal genital infection model, we therefore used a replication-
competent mutant of HSV-2, strain 186ΔKpn, which contains a
deletion in the UL23 gene encoding the viral thymidine kinase (TK)
and is attenuated for neurovirulence (Jones et al., 2000). Following
intravaginal infection of BALB/c mice with HSV-2 186ΔKpn virus,
we observed that increasing doses of challenge virus resulted in
uniform moderate genital disease (Fig. 1A). We determined that, in
animals receiving doses of 1.7105 PFU/mouse or greater, every
animal showed genital disease. Symptoms did not appear as severe
as those from infection with WT HSV-2 (Dudek et al., 2008, 2011;
Morrison et al., 1998) in that they did not reach the most severe
stages of disease, and they subsided within a few days, with animals
returning to a normal healthy state within a week after intravaginal
challenge (Fig. 1A). Similarly, viral shedding was detected in every
animal, peaking at 2–3 days post infection (dpi) and decreasing by
6–7 dpi (Fig. 1B). Thus, this system provided a non-lethal murine
infection model for HSV-2 genital disease that approximated acute
human infection and disease.Quantitative assay for latent HSV-2 DNA
To evaluate latent infection in this animal model, we wished to
establish a very sensitive quantitative PCR assay for viral DNA.
Based on our previous results (Jones et al., 2000), we expected low
copy numbers of latent HSV-2 186ΔKpn in dorsal root ganglia. To
distinguish the vaccine DNA from that of the challenge virus, we
designed primers for the UL29 gene (deleted in dl5-29) and com-
pared viral DNA puriﬁed in different ways as templates for qPCR
standard curve reactions. We observed that HSV-2 DNA puriﬁed by
sodium iodide double-banding (Colgrove et al., 2014) was the best
template for standard curves in that it allowed linear detection of
viral DNA over 6 logs (1100–1106 copies) with PCR efﬁ-
ciencies above 90% (Fig. 2A). This outperformed HSV-2 DNA pur-
iﬁed from nuclear extracts or PCR amplicons that allowed linear
ranges of detection of 5 logs (1101–1106 copies) and efﬁ-
ciencies of 93% and 87% respectively (results not shown). Using
this qPCR assay, we were able to detect as few as 3.8 copies per
reaction of the UL29 gene in DNA extracted 30 dpi from DRGs of
mice intravaginally infected at the dose of challenge virus that
produced disease in all mice (1.7105 PFU/mouse) (Fig. 2B).
Establishment of an ELISA for anti-ICP8 (UL29) antibodies
To evaluate protection from infection, we wished to distinguish
seroconversion due to immunization from seroconversion gener-
ated in response to challenge virus infection. Because the dl5-29
virus does not encode the ICP8 protein (UL29 gene), we set up an
ELISA to detect anti-ICP8 antibodies. We produced a recombinant
HSV-1 FLAG-tagged ICP8 protein in insect cells (Bryant et al., 2012)
as an antigen to coat plates (Fig. 3A). Different amounts of ICP8,
Fig. 2. Development of a sensitive PCR assay to detect latent HSV-2 DNA. (A) A representative qPCR standard curve generated using NaI gradient double-banded HSV-2 DNA
and ICP8 primers and probes showing 6 logs of detection with a lower limit of 1 copy/reaction and an efﬁciency of 96%, (B) An independent experiment showing detection of
latent HSV-2 DNA in mouse DRGs infected with HSV-2 186ΔKpn. Green circles correspond to standard points ranging from 2 to 2106 copies. Black crosses correspond to
values for experimental samples determined to contain from 3.8 to 12 copies per reaction.
Fig. 3. Development of an ELISA to detect HSV ICP8-speciﬁc antibody. (A) Recombinant ICP8-FLAG protein used for coating ELISA plates. Two independent preparations of
HSV-1 ICP8 protein were produced in insect cells and puriﬁed with an anti-FLAG antibody. Shown is a gel stained with Simply Blue Coomassie blue. The positive control lane
is a preparation used in a previous biochemical study (Bryant et al., 2012), (B) ELISA titers for anti-ICP8 antibodies from mice inoculated with HSV-2 186ΔKpn virus delivered
intravaginally. n¼5 mice/group, plot shows mean titer7SEM.
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anti-ICP8 mouse monoclonal antibody 39 S (Showalter et al., 1981)
as a positive control and sera from uninfected mice as background
controls. We determined that 150 ng/well of ICP8 recombinant
protein resulted in an optimal assay response based on the signal
to background ratio (results not shown). When we tested sera
from mice infected intravaginally with increasing doses of chal-
lenge virus, we observed increasing titers of anti-ICP8 antibodies
(Fig. 3B), showing that HSV-2 in general and strain 186ΔKpn in
particular can elicit antibodies against ICP8. Although we observed
some background with this ELISA that may be due to the purity or
nature of our antigen, we were able to measure signiﬁcant
increases above this background level upon infection with the TK
mutant virus. Preimmune sera also showed the same levels of
background, which we show as baseline in our results.
Protection from disease and seroconversion
Having established a non-lethal model for genital herpes in
mice and assays to measure various aspects of infection, we tested
whether immunization with dl5-29 could protect against sero-
conversion. BALB/c mice were immunized either subcutaneously
(SQ) or intramuscularly (IM) with 1105 PFU of HSV-2 dl5-29.
Animals were then challenged with 3105 PFU of HSV-2
186ΔKpn intravaginally 4 weeks after the second immunization,
and we measured disease daily on days 1–14 and viral shedding in
the genital tract 1–7 dpi. In animals immunized by the IM route,we observed complete protection from genital disease (Fig. 4A)
and reduced shedding into the vaginal cavity (Fig. 4B). In animals
immunized by the SQ route, we observed reduction of genital
disease and viral shedding (Fig. 4).
When we tested sera for anti-ICP8 antibodies, we found that
the mock-vaccinated mice showed a signiﬁcant increase in anti-
body titers or seroconversion (p Value¼0.001) (Fig. 4C), which
paralleled the observed genital herpetic disease. In contrast,
immunized animals showed reduced or no increase in anti-ICP8
antibody titers. Immunization via the IM route protected more
efﬁcaciously against vaginal infection (Fig. 4C, SQ p Value¼0.0052,
IM p Value¼0.2234).
Protection from latent infection
Having shown that the 186ΔKpn virus can establish latent
infection in sacral ganglia, we tested if immunization could protect
the mice from latent infection after vaginal challenge with HSV-2
186ΔKpn virus. At 30 dpi, we collected dorsal root ganglia where
the cell bodies of neurons innervating the site of infection are
located. Quantitative PCR analysis showed that, in mock-
vaccinated animals, HSV-2 186ΔKpn established latent infection
(Fig. 5). In contrast, both SQ and IM immunization greatly reduced
latent infection of ganglia when compared to mock immunization
(p Values¼0.0028 and 0.0026, respectively) with the IM route
being slightly more effective than the SQ route, although differ-
ences between them were not signiﬁcant (p¼0.8619; Fig. 5).
Fig. 4. Protection against disease, virus shedding, and seroconversion. Mice were
immunized intramuscularly (IM) or subcutaneously (SQ) with HSV-2 dl5-29 or
mock-immunized and challenged intravaginally with HSV-2 186ΔKpn virus.
(A) Disease Scores, (B) Viral shedding into the vaginal cavity, (C) ELISA titers. n¼10
(mock-vaccinated) or 9 (vaccinated groups) mice/group, plots show mean7SEM. p
Values: Mock¼0.001, SQ¼0.0052, IM¼0.2234.
Fig. 5. Protection against latent infection. At 30 days after challenge with HSV-2
186ΔKpn, DNA was collected from the dorsal root ganglia of BALB/c mice. In two
independent experiments, we measured latent viral DNA in all mock-vaccinated
animals. Results are expressed as copies of viral DNA per microgram of total DNA.
ICP8 was used to measure viral DNA copies. Murine adipsin was used as an internal
control. Dotted line shows the lower limit of detection of 2 copies/reaction. n¼10
(mock-vaccinated) or 9 (vaccinated groups) mice/group, plot shows mean7SEM.
Mock-vaccinated group was signiﬁcantly higher that both SQ and IM vaccinated
groups (p¼0.0028 and 0.0026 respectively).
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during acute infection, protection against latent infection can be
achieved.
We had hypothesized that the three parameters of protection
were related; therefore, we performed pairwise comparisons of
the values for protection. We observed a signiﬁcant correlation
between viral shedding and anti-ICP8 antibody titers (po0.001)
with a moderately strong linear correlation (r¼0.7972) (Fig. 6A).
We also observed a statistically signiﬁcant correlation between
latent viral DNA load and anti-ICP8 antibody titers (po0.0001)
with a moderately strong linear correlation (r¼0.7021) (Fig. 6B).
Finally, we observed a statistically signiﬁcant correlation between
viral shedding and latent viral DNA load (po0.0162) with amoderate linear correlation (r¼0.4582). Therefore, in general,
there was a correlation between the three values used for mea-
suring protection from infection.Discussion
Viral vaccines have usually protected against viral disease but
have not protected completely against infection. The existing viral
vaccines are used mostly for viruses that cause an acute infection,
which could be cleared by the host immune response. In contrast,
viruses that establish a latent infection, such as the herpesviruses
and HIV, are more difﬁcult vaccine targets because, even if disease
is prevented, latent infection may still be established, from which
the virus could reactivate and cause disease. For herpesviral vac-
cines, there has been debate about the type of protection that
should be measured in clinical trials, i.e., whether it should be
protection against disease or infection, the latter being measured
by seroconversion (Dropulic and Cohen, 2012; Gershon, 2013;
Johnston et al., 2014; Knipe et al., 2014).
In this study we established a non-lethal model of genital HSV-
2 infection that allowed measurement of long-term protection,
including protection against disease, viral replication at the pri-
mary mucosal site, seroconversion and latent infection. We
established a sensitive PCR assay that can detect very low levels of
HSV-2 DNA, and we used this system to assess protection against
various aspects of HSV-2 genital infection. We used the HSV-2 dl5-
29 replication-defective viral vaccine candidate for immunization,
and, because this virus does not encode the HSV-2 ICP8 protein
(UL29 gene product), we established an ELISA system to measure
antibody responses to ICP8 as evidence of wildtype virus infection.
We observed that immunization with dl5-29 reduces disease, viral
shedding, seroconversion and latent infection. Therefore, it is
feasible to model a non-lethal infection in mice.
Protection against disease
Protection against disease in murine genital infection models
usually has involved measurement of protection against death
(Parr et al., 1994). In this system we have deﬁned a dose that
causes genital disease in all mice but with 100% survival. This is
based on the inability of TK mutants to replicate in sensory
neurons and cause neurological disease (Coen et al., 1989). This
Fig. 6. Correlation of protection from acute and latent infection. Pairwise com-
parisons of the three protection parameters were evaluated for all animals in this
study. (A) Viral shedding versus anti-ICP8 titers, (B) Copies of latent viral DNA in
DRGs versus anti-ICP8 titers, (C) Viral shedding versus copies of latent viral DNA in
DRGs. Pearson coefﬁcients (r) and p-Values (p) were calculated as described in
Materials and Methods.
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permissive for HSV replication than mouse neurons.
Protection against infection
Protection against infection can be measured at various levels.
In experimental models, it is feasible to measure viral infection by
assessment of viral shedding from the genital tract. In this and
probably all murine systems, immunization reduces shedding
from the genital tract but does not prevent recovery of infectious
virus from the genital tract (Morrison et al., 1998). While some of
this virus at day 1 may represent input virus, increased levels of
virus at day 2 are likely due to viral replication. Therefore,sterilizing immunity is not achieved, but reduced replication at the
primary site of infection reduces or prevents latent infection as
described below.
Measurement of viral shedding is usually not feasible in large
clinical trials. Instead, seroconversion can be measured. However,
this has not been measured in murine genital infection systems
because HSV-2 infections are lethal in mice. In our study employing
a TK mutant virus, we observed that immunization with dl5-29
did prevent increased antibody responses speciﬁc to ICP8. Thus,
protection against seroconversion is feasible in mice, even when
sterilizing immunity is not achieved.
Protection against latent infection
In this study we observed reduction or even prevention of latent
infection of sacral ganglia in immunized animals but not in the
control group. The TK challenge virus, although attenuated, is
capable of establishing latent infection in mock-vaccinated mice.
Therefore, it is possible, at least in this mouse model, to achieve
protection against latent infection without completely preventing
viral replication at the primary site of infection. Concerns have been
expressed about the possibility of preventing disease without
reducing latent infection, which could raise the incidence of
asymptomatic infection (Rupp and Bernstein, 2008). Studies in mice
and guinea pigs utilizing dl5-29 for immunization have found a
reduction in latent infection and recurrent disease when disease
and viral shedding are reduced (Hoshino et al., 2005, 2008, 2009;
Jones et al., 2000). In this study we observed a correlation between
reductions in viral shedding, anti-ICP8 antibody titers, and latent
viral DNA load. Therefore, these results predict that reduction in
viral acute infection and seroconversion will reduce HSV latent
infection, but this will need to be examined in the human situation.
In summary, immunization of mice with the HSV-2 dl5-29 virus
can provide protection against seroconversion and latent infection,
even if viral replication does occur in the genital tract. Thus, it may
be feasible to use a reduction of seroconversion as a clinical end-
point in a clinical trial of an HSV-2 vaccine. Nevertheless, it still
seems prudent to have disease as the primary endpoint and sero-
conversion as a secondary endpoint because approval of products
by the FDA is based on clinical parameters. Measurement of pro-
tection against seroconversion using dl5-29 virus as the immu-
nogen presents a challenge in that it expresses all but two viral
gene products. We used an ICP8 antibody ELISA measurement in
this study, but the ELISA as constituted is not optimal because it
has a limited dynamic range. Antibody responses to ICP8 may be
more robust in humans, but, if not, a different assay for ICP8-
speciﬁc antibodies such as the luciferase immunoprecipitation
assay (Burbelo et al., 2009) might be used. Alternatively, additional
viral genes could be deleted from the dl5-29 virus, an approach
that we are now attempting.Methods
Cells and viruses
Vero cells (ATCC CCL-81) were used for propagation and titration
of replication-competent virus stocks (Spang et al., 1983). The V5-29
complementing cell line (Da Costa et al., 2000) was used for pro-
pagation and titration of replication-defective viruses. The HSV-2
dl5-29 replication-defective virus was generated from HSV-2
186synþ by deletions of the essential UL5 and UL29 ORFs (Da
Costa et al., 1997, 2000). The HSV-2 186ΔKpn UL23 gene (TK)
deletion mutant virus was described previously (Jones et al., 2000).
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Animal housing and experiments were conducted according to
protocols approved by the Harvard Medical Area Standing Com-
mittee on Animals.
Immunization and genital infections
Genital infections
5-week-old female BALB/c mice were bled from the tail vein
before any injection and then administered two doses of 3 mg of
Depo-Provera 1 week apart. One day after the second dose of
Depo-Provera, the vaginal cavities were then pre-swabbed, and
the indicated doses of the attenuated HSV-2 strain 186ΔKpn were
delivered in a 10 μl volume using a micropipettor as described
(Morrison et al., 1998). Animals were monitored for herpetic dis-
ease daily on days 1–14. At day 21 post challenge, mice were
bled again.
Immunization
For protection assays, 5-week-old female BALB/c mice were
immunized twice subcutaneously (SQ) in the rear ﬂank or intra-
muscularly (IM) in the gastrocnemius muscle, on days 0 and 28,
with 105 plaque-forming units (PFU) of extracellular dl5-29 virus
in a 50 μl volume in PBS as described previously (Delagrave et al.,
2012; Dudek et al., 2011; Morrison et al., 1998). On days 48 and 55,
mice were injected subcutaneously in the scruff of the neck with
3 mg of Depo-Provera in a 100 μl volume. At 4 weeks after the
second immunization (day 56), the vaginal cavities were pre-
swabbed with a wet polyester swab, and mice were challenged
intravaginally with the indicated doses of HSV-2 186ΔKpn
TK virus.
Measurement of viral shedding
On days 1–7 post-intravaginal challenge, the vaginal cavities of
the mice were successively swabbed twice with pre-wetted
polyester swabs (Puritan, #25-800D50). The swabs were placed
in 1 ml of assay medium (DMEM, 0.1% glucose, 1% FCS, 5% glycerol)
and stored at 80 °C. Viral titers were determined by standard
plaque assay on Vero cells (Morrison et al., 1998).
Clinical disease measurement
Mice that were challenged with wild-type HSV-2 were
observed on days 1-14 post infection for signs of genital lesions
and systemic illness, as described previously (Morrison et al.,
1998). The severity of disease was scored as follows: 0¼no sign of
disease, 1¼slight genital erythema and edema, 2¼moderate
genital inﬂammation, 3¼purulent genital lesions, 4¼hind-limb
paralysis. Mice were euthanized with CO2 at the ﬁrst sign of
paralysis.
Measurement of seroconversion
Assay for anti-ICP8 (UL29) antibodies
The ICP8 (UL29) protein from HSV-1 was produced in Sf21
insect cells infected with a baculovirus encoding a FLAG-tagged
version of ICP8 as described previously (Bryant et al., 2012). The
purity of the protein was assessed by running an aliquot from each
step of the puriﬁcation protocol in a polyacrylamide gel and
staining with SimplyBlue stain (Life Technologies LC6060). Max-
iSorp plates were coated with varying amounts of ICP8-FLAG (3–
300 ng/well) and used for ELISA with the 39 S mouse monoclonal
anti-ICP8 antibody, preimmune mouse serum, or serum from mice
infected intravaginally with HSV-2 186ΔKpn. All subsequent ICP8
ELISA plates were coated with 150 ng/well of ICP8-FLAG protein.
ELISA for ICP8 was carried as below.ELISA
Mouse sera were prepared using BD Microtainer tubes (BD,
Ref# 365956). Total anti-HSV-2 and anti-ICP8 antibodies titers
were determined by ELISA on 96-well ﬂat-bottomed plates (Nunc,
MaxiSorp) coated with 50 ng/well of puriﬁed HSV-2 (Advanced
Biotech, Cat# 10-146-000) or 150 ng/well of ICP8-FLAG in 50 μl of
carbonate–bicarbonate buffer pH 9.6. Bound antibodies in sera
were detected by alkaline phosphatase-conjugated rabbit anti-
mouse antibody followed by p-Nitrophenyl phosphate (Sigma,
Cat# A4312, N2770) and measuring absorbance at 405 nm
according to the manufacturer instructions. The endpoint titer was
determined according to Frey et al. (1998).
Measurement of latent viral DNA load
Dorsal root ganglia were harvested at 30 dpi (Malin et al.,
2007), and DNA was puriﬁed from 10 DRGs per sample with the
DNeasy blood and tissue kit (Qiagen, #69506). Levels of latent viral
DNA in DRGs were measured using TaqMan real-time PCR to
detect the HSV-2 UL29 (ICP8) gene, which is present in the chal-
lenge virus HSV-2 186ΔKpn but not in the vaccine vector dl5-29,
and the mouse adipsin gene as an internal control. Standard curve
samples were prepared using HSV-2 DNA puriﬁed by double
banding in sodium iodide gradients as described previously (Col-
grove et al., 2014; Walboomers and ter Schegget, 1976) and mouse
genomic DNA as the source of the adipsin gene. The standard
curve and DRG samples were run in triplicate using the following
primers and probes in duplex reactions, mouse adipsin primers:
forward 5'-GCAGTCGAAGGTGTGGTTACG-3'; reverse 5'-GGTATA-
GACGCCCGGCTTTT-3'. The probe for adipsin, with reporter dye,
was 5'- VIC-CTGTGGCAATGGC-MGBNFQ-3' (MGBNFQ, minor
groove binder non-ﬂuorescent quencher) (Awasthi et al., 2011).
Primers for ICP8 with nucleotide positions based on HSV-2 strain
HG52: forward 5'-TTTTGGCTTCTCGGACTACG-3' (62082-62063);
reverse 5'-ATCACCAGATACAGCAAGGC-3' (61966-61985). The
probe for ICP8 was 5'- 6FAM-TGCGACCTAAAACAC-MGBNFQ-3'
(62051-62037). Reactions were performed on 5 μl of DNA (250–
300 ng) in 25 μl reaction mixtures, using TaqMan Gene Expression
Master Mix (Life Technologies Cat#: 4369016) and ABI 7300 and
StepOne Plus Real Time PCR Systems.
Statistical analysis
All statistical analyses were performed with GraphPad Prism.
Statistical signiﬁcance was evaluated with Student t-tests and the
mean7SEM is plotted in all the ﬁgures.
Correlation coefﬁcients (r) were calculated with a two-tailed
Pearson test, and correlation signiﬁcance is reported based on the
p Value.Acknowledgments
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